TMO · Thermo Fisher Scientific

514 filings

TMO SEC Filings

Thermo Fisher Scientific - 514 total filings

Filing record · 2016–202610-K1110-Q338-K153

Showing 1–50 of 514 filings

Thermo Fisher Scientific 8-K Report, Executive Changes (Oct 30, 2026)

Thermo Fisher Scientific Inc. (TMO) filed an 8-K on October 30, 2026, reporting a key executive departure. Michael D. Shafer, Executive Vice President, is set to retire from his role effective December 31, 2026. This filing primarily serves as a notification of this leadership change, indicating the company is preparing for a transition in its senior management team. While no other significant financial or operational updates are provided in this specific filing, investors should note the timing of this retirement. Understanding the responsibilities held by Mr. Shafer and the company's succession plan will be crucial for assessing the impact of this departure on Thermo Fisher's future operations and strategic direction. Further details regarding his successor or any changes in divisional oversight are expected to be disclosed in subsequent filings or communications.

Oct 30, 2026 10-Q

Thermo Fisher Scientific Quarterly Report for Q3 Ended Sep 26, 2026

Thermo Fisher Scientific Inc. reported strong financial results for the nine months ended September 26, 2026, demonstrating robust revenue growth and improved profitability. Total revenues increased by 9% year-over-year, reaching $35.14 billion, driven by broad-based strength across its segments, particularly Laboratory Products and Biopharma Services and Life Sciences Solutions. The company's operational efficiency and strategic acquisitions contributed significantly to its performance. Adjusted operating income grew by 12% to $8.10 billion, with adjusted operating income margin expanding to 23.1%. This growth reflects strong productivity improvements and successful integration of recent acquisitions, notably Clario Holdings, Inc. Financially, Thermo Fisher maintained a solid balance sheet, though total debt increased to $41.37 billion. The company generated substantial operating cash flow of $5.87 billion and free cash flow of $4.62 billion, underscoring its ability to fund operations, investments, and shareholder returns. The company also repurchased $4.00 billion in common stock and paid $0.51 billion in dividends, indicating a commitment to returning value to shareholders.

Oct 30, 2026 8-K

Thermo Fisher Scientific 8-K Report, Financial Results (Oct 21, 2026)

Thermo Fisher Scientific Inc. (TMO) reported strong third quarter 2026 financial results on October 21, 2026. The company achieved a 9% increase in revenue, reaching $12.14 billion, with a notable 6% driven by organic growth. Both GAAP Diluted Earnings Per Share (EPS) and Adjusted EPS saw significant year-over-year increases, growing 9% to $4.64 and 15% to $6.68, respectively. The company highlighted its successful execution of a proven growth strategy, evidenced by the launch of innovative new products across various segments and strengthened customer partnerships. Strategic capital deployment was also a focus, including the completion of a business divestiture. Management expressed confidence in delivering an excellent full year 2026, emphasizing continued long-term value creation for stakeholders.

Oct 21, 2026 10-Q

Thermo Fisher Scientific Quarterly Report for Q2 Ended Jun 27, 2026

Thermo Fisher Scientific Inc. (TMO) reported strong financial results for the quarter and six months ended June 27, 2026, demonstrating robust revenue growth and improved profitability. Total revenues increased by 10% in the quarter and 8% for the year-to-date period, driven by strong performance across its diverse business segments, particularly Life Sciences Solutions and Laboratory Products and Biopharma Services. The company saw significant contributions from recent acquisitions, notably Clario Holdings, Inc., which bolstered its clinical research offerings. Profitability metrics also showed improvement, with GAAP operating income up 14% for the quarter and adjusted operating income margin expanding by 90 basis points. This growth was attributed to strong productivity improvements, successful integration of acquisitions, and favorable market conditions in key end markets like pharmaceutical and biotech. The company's strategic focus on innovation, customer partnerships, and its commercial engine continues to yield positive results, positioning Thermo Fisher for sustained growth.

Jul 31, 2026 8-K

Thermo Fisher Scientific 8-K Report, Financial Results (Jul 23, 2026)

Thermo Fisher Scientific reported second-quarter 2026 results (quarter ended June 27, 2026) with revenue of $11.99 billion, up 10% from $10.86 billion a year earlier. Organic revenue growth was 5%, so roughly half of the growth came from acquisitions, with a 1-point currency tailwind. GAAP diluted EPS rose 9% to $4.68, and adjusted EPS rose 13% to $6.03. GAAP operating margin expanded to 17.4% from 16.9%, and adjusted operating margin reached 22.8% from 21.9%. Free cash flow was $1.68 billion versus $1.11 billion, and first-half free cash flow was $2.50 billion, up about 69%. Segment results were strongest in Life Sciences Solutions, where adjusted segment margin reached 37.0%, and in Analytical Instruments, where segment margin rose to 23.0% from 18.8%. The balance sheet shows the scale of recent capital deployment. Cash fell to $4.06 billion from $9.85 billion at year-end 2025, reflecting $8.87 billion of acquisition spending and $4.0 billion of share repurchases in the first half. Goodwill rose by about $5.5 billion and acquisition-related intangibles by about $2.8 billion, and long-term obligations increased to $39.2 billion from $35.9 billion. The company also disclosed the divestiture of its microbiology business and $1.0 billion of stock repurchases during the quarter. Investors will want to focus on the leverage implications and on the integration progress of recent deals. The filing itself does not include updated 2026 guidance. Management said it would provide revised full-year guidance on the earnings call held the same morning, so the market reaction will depend on that outlook. The filing also does not name the acquired business. The earnings release is furnished under Item 2.02 and is not deemed filed under Section 18 of the Exchange Act.

Jul 23, 2026 8-K

Thermo Fisher Scientific 8-K Report, Shareholder Vote Results (May 26, 2026)

Thermo Fisher Scientific Inc. (TMO) filed an 8-K on May 26, 2026, detailing the outcomes of its Annual Meeting of Shareholders held on May 20, 2026. The primary focus of the filing is the voting results on key corporate matters. Notably, all incumbent nominees for the Board of Directors were overwhelmingly re-elected for one-year terms, indicating strong shareholder confidence in the current leadership and governance structure. However, a significant development from the meeting is the shareholder rejection of the non-binding, advisory proposal on the compensation of the Company's named executive officers. This outcome suggests a divergence of opinion between shareholders and the board regarding executive pay practices. Despite this advisory vote, the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, was ratified by a substantial majority of shareholders, ensuring continued auditor oversight.

May 26, 2026 10-Q

Thermo Fisher Scientific Quarterly Report for Q1 Ended Mar 28, 2026

Thermo Fisher Scientific Inc. reported strong revenue growth of 6% for the first quarter of 2026, reaching $11.0 billion, driven by robust performance in the pharmaceutical and biotech sectors. While overall revenue saw a healthy increase, the academic and government, and diagnostics and healthcare markets experienced declines. The company demonstrated significant strategic activity with the acquisition of Clario Holdings, Inc. for $9.099 billion, expanding its clinical trial data solutions capabilities. Conversely, Thermo Fisher also announced the divestiture of its microbiology business for approximately $1.075 billion, expected to close in the second half of 2026. These strategic moves, alongside a substantial $3 billion in share repurchases and $0.16 billion in dividends paid, highlight the company's active capital allocation strategy.

May 1, 2026 8-K

Thermo Fisher Scientific 8-K Report, Financial Results (Apr 23, 2026)

Thermo Fisher Scientific (TMO) reported first quarter 2026 results for the period ended March 28, 2026. Revenue grew 6% to $11.01 billion, though organic revenue growth was only 1%; the remaining growth came from acquisitions (3 points, largely the Clario acquisition) and currency translation (2 points). GAAP diluted EPS rose 11% to $4.43, and adjusted EPS rose 6% to $5.44. GAAP operating margin improved to 16.9% from 16.6%, while adjusted operating margin was roughly flat at 21.8% versus 21.9% a year earlier. Adjusted operating income grew 6% to $2.40 billion. Cash generation and capital deployment were the notable features of the quarter. Operating cash flow was $1.19 billion and free cash flow was $825 million, more than double the prior year's $373 million. The company spent $8.87 billion on acquisitions, primarily Clario, and repurchased $3.0 billion of stock. Funding came largely from new debt, with long-term obligations rising to $40.07 billion from $35.85 billion at year-end 2025, and cash fell sharply to $3.25 billion from $9.85 billion. Goodwill and acquisition-related intangibles increased substantially, which raises future impairment and integration considerations. The company did not provide updated 2026 guidance in the filing; it said guidance would be presented on the earnings call the same morning. Investors should therefore review the call commentary and updated guidance alongside these results to assess whether the acquisition-driven growth and elevated leverage are consistent with management's full-year outlook.

Apr 23, 2026 8-K

Thermo Fisher Scientific 8-K Report, Corporate Update (Mar 24, 2026)

On March 24, 2026, Thermo Fisher Scientific (NYSE: TMO) disclosed in an 8-K (Item 8.01, with press release Exhibit 99.1) that it has completed its acquisition of Clario Holdings, Inc., a provider of endpoint data solutions for clinical trials. The headline purchase price is $8.875 billion in cash at closing. Thermo Fisher also agreed to pay $125 million in January 2027 and up to $400 million in earn-out payments tied to Clario's performance in 2026 and 2027, so total consideration could exceed the closing price if milestones are met. Clario will be integrated into the Laboratory Products and Biopharma Services segment. The seller group was led by Astorg and Nordic Capital, with Novo Holdings and Cinven also among the sellers. Management characterizes the deal as strategically complementary to Thermo Fisher's clinical research offerings and reports a double-digit internal rate of return. Clario is expected to grow in the high single digits and to be accretive to adjusted operating margin. Management expects the business to contribute $0.45 of adjusted EPS in the first year after close, with synergies of approximately $175 million of adjusted operating income by year five, primarily from revenue synergies. Detailed 2026 financial impact is deferred to the first-quarter 2026 earnings call. The filing contains no GAAP earnings guidance for the transaction, and the release notes that adjusted measures exclude acquisition-related items and amortization. For investors, the key points are the size of the cash outlay relative to Thermo Fisher's scale (annual revenue above $40 billion), the contingent payments that add to the total cost, and the reliance on revenue synergies to reach the stated return. The release also flags standard integration and forward-looking risks, including possible failure to realize expected benefits, customer and employee disruption at Clario, and difficulty retaining key staff.

Mar 24, 2026 10-K

Thermo Fisher Scientific Annual Report, Year Ended Dec 31, 2025

Thermo Fisher Scientific Inc. reported solid financial performance for the fiscal year ended December 31, 2025, with revenues reaching $44.56 billion, a 4% increase compared to the previous year. This growth was primarily driven by strong demand in the pharmaceutical and biotechnology sectors, although a slowdown in COVID-19 related product and service demand partially offset this. The company experienced robust productivity improvements across its segments, particularly in Laboratory Products and Biopharma Services and Life Sciences Solutions, leading to an increase in both GAAP operating income margin (17.4%) and adjusted operating income margin (22.7%). Strategic acquisitions in 2025, including Olink Holding AB and a filtration and separation business, are expected to enhance Thermo Fisher's capabilities and market position, particularly in high-growth areas like proteomics and bioproduction. While the company faces headwinds such as macroeconomic uncertainties impacting academic and government markets and increased costs due to inflation and tariffs, its diversified business model and focus on innovation position it well for continued growth. The company's financial position remains strong, supported by significant free cash flow generation and a substantial cash balance, enabling ongoing investments in R&D, strategic acquisitions, and shareholder returns.

Feb 26, 2026 8-K

Thermo Fisher Scientific 8-K Report, Material Agreement (Feb 12, 2026)

Thermo Fisher Scientific Inc. (TMO) has announced the successful completion of a significant public offering of senior notes, raising approximately $3.76 billion in net proceeds. This capital infusion comprises four tranches of notes with varying interest rates and maturity dates, ranging from 2031 to 2046. The primary stated purpose of this offering is to fund a portion of the cash consideration for the previously announced acquisition of Clario Holdings, Inc., underscoring the company's strategic growth initiatives. While the acquisition of Clario is subject to customary closing conditions and regulatory approvals, TMO has outlined plans for the proceeds. Pending the acquisition's completion, a portion of the funds may be allocated to general corporate purposes, including potential future acquisitions, debt repayment, working capital, capital expenditures, or share repurchases. The notes are unsecured general obligations of the company and rank equally with existing unsecured and unsubordinated debt. The filing also details provisions related to early redemption, change of control scenarios, and standard covenants limiting certain secured debt and major asset dispositions.

Feb 12, 2026 8-K

Thermo Fisher Scientific 8-K Report, Financial Results (Jan 29, 2026)

Thermo Fisher Scientific (TMO) reported fourth quarter and full year 2025 results on January 29, 2026, with revenue growing 7% to $12.21 billion in Q4 and 4% to $44.56 billion for the full year. Q4 GAAP diluted EPS rose 9% to $5.21 and adjusted EPS rose 8% to $6.57. For the full year, GAAP diluted EPS was $17.74 (up 7%) and adjusted EPS was $22.87 (up 5%). Organic revenue growth was a more modest 3% in Q4 and 2% for the full year, meaning acquisitions and currency translation contributed the majority of top-line growth. Adjusted operating margin was broadly stable at 22.7% for the year versus 22.6% in 2024, while Q4 adjusted margin contracted slightly to 23.6% from 23.9%. Management emphasized an active capital deployment year, with roughly $16.5 billion deployed in 2025, including $13 billion committed to M&A such as the Solventum Filtration and Separation business, Sanofi's Ridgefield sterile fill-finish site, and a definitive agreement to acquire Clario. Shareholders received $3.6 billion through buybacks and dividends. Balance sheet changes were significant: cash rose to $9.85 billion and long-term obligations increased to $35.85 billion from $29.06 billion, reflecting debt issued to fund acquisitions. Full year free cash flow declined to $6.34 billion from $7.32 billion, driven by higher capital expenditures and working capital changes. The company did not disclose 2026 guidance in the press release, deferring it to the earnings call held the same morning. Investors should therefore focus on the call commentary for 2026 revenue, EPS, and margin expectations, as well as the integration progress and returns on the recent acquisitions and the Clario deal's contribution to organic growth going forward.

Jan 29, 2026 8-K

Thermo Fisher Scientific 8-K Report, Executive Changes (Jan 12, 2026)

Thermo Fisher Scientific Inc. (TMO) has announced significant changes to its executive leadership team through an 8-K filing. Two long-serving executives, Michel Lagarde (Executive Vice President and Chief Operating Officer) and Frederick M. Lowery (Executive Vice President), are departing to pursue other opportunities. Mr. Lagarde's last day will be March 31, 2026, and Mr. Lowery's will be February 28, 2026. These departures coincide with a planned organizational restructuring and leadership transition effective March 1, 2026. Marc N. Casper will assume the combined role of Chairman and Chief Executive Officer. Gianluca Pettiti is promoted to President and Chief Operating Officer, and Michael Shafer will move into an expanded role reporting directly to the CEO. Investors should monitor how these leadership changes and structural adjustments impact the company's strategic execution and operational efficiency in the coming quarters.

Jan 12, 2026 8-K

Thermo Fisher Scientific 8-K Report, Material Agreement (Dec 1, 2025)

Thermo Fisher Scientific Inc. (TMO) announced the issuance of €1.0 billion in Floating Rate Senior Notes due 2027 and €1.1 billion in 3.628% Senior Notes due 2035 by its indirect wholly-owned finance subsidiary, Thermo Fisher Scientific (Finance I) B.V. The Company is fully and unconditionally guaranteeing these notes on a senior unsecured basis. This transaction represents a significant capital raise totaling approximately €2.1 billion in net proceeds after expenses. The proceeds from this offering are intended for general corporate purposes, including potential acquisitions, debt repayment, working capital needs, capital expenditures, or equity repurchases. The company may also temporarily invest these proceeds in short-term liquid investments. The issuance of these notes provides Thermo Fisher with substantial financial flexibility for strategic initiatives and operational needs.

Dec 1, 2025 10-Q

Thermo Fisher Scientific Quarterly Report for Q3 Ended Sep 27, 2025

Thermo Fisher Scientific Inc. (TMO) reported solid financial results for the nine months ended September 27, 2025, with total revenues increasing by 3% year-over-year to $32.34 billion. Net income attributable to Thermo Fisher Scientific Inc. grew to $4.74 billion, a 5.3% increase from the prior year period. The company demonstrated strong operational execution, reflected in an increase in both GAAP and adjusted operating income margins, driven by significant productivity improvements across its segments. The company continued its strategic growth initiatives, including targeted acquisitions. Notable acquisitions during the period include the Filtration and Separation business from Solventum Corporation and Olink Holding AB. Management also highlighted ongoing efforts to streamline operations through restructuring actions, primarily in the Laboratory Products and Biopharma Services segment. Despite some market headwinds, such as customer hesitancy in the academic and government sector and challenges in China's diagnostics and healthcare market, Thermo Fisher's diversified business model and strong execution in core markets like pharma and biotech have driven performance.

Oct 31, 2025 8-K

Thermo Fisher Scientific 8-K Report, Corporate Update (Oct 29, 2025)

On October 29, 2025, Thermo Fisher Scientific (TMO) disclosed a definitive agreement to acquire Clario Holdings, Inc., a provider of endpoint data solutions for clinical trials, from a shareholder group led by Astorg and Nordic Capital, Novo Holding, and Cinven. The consideration is $8.875 billion in cash at closing, plus a $125 million deferred payment due in January 2027 and up to $400 million in earn-out payments tied to Clario's performance in 2026 and 2027. Clario is expected to generate about $1.25 billion of revenue in 2025, which implies roughly 7.1x revenue on the closing cash price before deferred and contingent payments. Management says the deal is immediately accretive to adjusted EPS after closing and adds $0.45 of adjusted EPS in the first year. They also expect a double-digit internal rate of return, high-single-digit growth under Thermo Fisher ownership, and about $175 million of adjusted operating income from synergies by year five, mainly from revenue synergies. Clario will join the Laboratory Products and Biopharma Services segment. The company plans to fund the deal with debt financing and cash on hand, and closing is expected by the middle of 2026, subject to customary conditions and regulatory approvals. For investors, the key questions are the scale of new debt, whether the accretion and synergy targets are achieved, and execution risk around integration and regulatory review. The filing's forward-looking statements flag these risks, including possible failure to obtain approvals, business disruption at Clario, employee retention, and shortfalls in expected synergies. The 8-K does not disclose the purchase price allocation, the amount of new debt, or Clario's profitability, so those details will matter for assessing the deal's returns.

Oct 29, 2025 8-K

Thermo Fisher Scientific 8-K Report, Financial Results (Oct 22, 2025)

Thermo Fisher Scientific (TMO) reported third quarter 2025 results for the fiscal quarter ended September 27, 2025. Revenue rose 5% year over year to $11.12 billion, with organic growth of 3%; acquisitions contributed about 1 point and currency about 1 point. GAAP diluted EPS was $4.27, essentially flat versus $4.25 a year earlier, while adjusted EPS grew 10% to $5.79. Adjusted operating margin expanded to 23.3% from 22.3%, while GAAP operating margin held roughly steady at 17.4% versus 17.3%. The gap between GAAP and adjusted results is driven mainly by amortization of acquisition intangibles ($435 million) and higher restructuring costs ($135 million versus $45 million). Cash generation and capital deployment were the other focus areas. Free cash flow was $1.84 billion, down from $1.92 billion, as capital expenditures rose to $404 million from $271 million. Over the first nine months, free cash flow fell to $3.32 billion from $4.50 billion, and organic growth for that period was 2%. During the quarter the company completed the acquisitions of Solventum's Filtration and Separation business and Sanofi's Ridgefield, New Jersey fill-finish site, and it repurchased $1.0 billion of stock. Total debt rose: short-term obligations were $3.82 billion and long-term obligations were $31.86 billion at quarter-end, compared with $2.21 billion and $29.06 billion at year-end 2024. Cash and equivalents fell to $1.98 billion from $4.01 billion. The company did not include updated 2025 guidance in the filing; management said it would provide it on the earnings call at 8:30 a.m. ET on October 22, 2025. Investors should therefore treat the guidance update, which is not contained in this 8-K, as the key forward-looking element to review alongside these results.

Oct 22, 2025 8-K

Thermo Fisher Scientific 8-K Report, Material Agreement (Oct 7, 2025)

Thermo Fisher Scientific Inc. (TMO) has filed an 8-K report announcing the issuance of a substantial amount of senior notes, totaling $2.5 billion, across four tranches with varying maturity dates and interest rates. This debt offering includes $500 million in 4.200% Senior Notes due 2031, $750 million in 4.473% Senior Notes due 2032, $750 million in 4.794% Senior Notes due 2035, and $500 million in 4.894% Senior Notes due 2037. The net proceeds from this offering are expected to be approximately $2.48 billion and are designated for general corporate purposes, including potential acquisitions, debt repayment, working capital, capital expenditures, or equity repurchases. From an investor's perspective, this filing signals Thermo Fisher's proactive approach to managing its capital structure and funding future growth initiatives. The diversification of maturity dates and interest rates suggests a strategic approach to debt management. While the notes are general unsecured obligations, they rank equally with existing and future unsecured and unsubordinated debt. Investors should note the covenants that restrict the company's ability to incur certain secured debt and engage in sale-leaseback transactions, as well as limitations on mergers and asset sales. The filing also outlines provisions for redemption by the company and a potential put option for noteholders in the event of a change of control coupled with a credit rating downgrade.

Oct 7, 2025 8-K

Thermo Fisher Scientific 8-K Report, Corporate Update (Sep 2, 2025)

On September 2, 2025, Thermo Fisher Scientific (NYSE: TMO) disclosed in an 8-K (Item 8.01, with the press release as Exhibit 99.1) that it completed its acquisition of the Purification & Filtration business of Solventum (NYSE: SOLV) for approximately $4.0 billion in cash. The business is now called Thermo Fisher's Filtration and Separation business and sits within the Life Sciences Solutions segment. It serves bioprocessing filtration, healthcare and industrial filtration, and membranes markets, and is expected to generate roughly $750 million of revenue in 2025. Management expects mid- to high-single-digit organic growth for the business, with margin expansion driven by the PPI Business System and meaningful synergy realization. The deal is expected to be dilutive to adjusted EPS by $0.06 in the first year, reflecting one-time stand-up costs and financing costs that offset day-one cost savings. Thermo Fisher targets about $125 million of adjusted operating income from revenue and cost synergies by year five, and it cites an anticipated double-digit internal rate of return. The transaction was reduced in scope earlier in 2025: the Drinking Water Filtration business was removed, closing consideration was cut by $100 million, and Solventum may pay Thermo Fisher up to $75 million tied to a future sale of that business or after three years. The filing itself is brief and mainly furnishes the press release; it contains no new financial statements. Investors will mainly watch integration execution, whether synergies and margin targets are met, and the effect of the purchase on near-term EPS.

Sep 2, 2025 10-Q

Thermo Fisher Scientific Quarterly Report for Q2 Ended Jun 28, 2025

Thermo Fisher Scientific Inc. reported solid revenue growth in the second quarter and first half of 2025, driven by strong performance in its Life Sciences Solutions and Laboratory Products and Biopharma Services segments. While overall revenue increased by 3% and 2% respectively for the periods, the company's profitability metrics showed some mixed signals. Operating income saw marginal increases, but operating income margins experienced slight declines, attributed to unfavorable business mix, strategic investments, and tariff impacts. The company also announced a significant pending acquisition of Solventum Corporation's Purification and Filtration business for approximately $4.0 billion, expected to close by year-end 2025, which will further bolster the Life Sciences Solutions segment. Despite a slight decrease in free cash flow compared to the prior year, driven by increased debt issuance and share repurchases, Thermo Fisher maintains a strong liquidity position and expects to meet its cash requirements. The company continues to execute its growth strategy focused on innovation, customer partnerships, and its commercial engine, while managing costs through productivity improvements and restructuring efforts. Investors should monitor the integration of recent and pending acquisitions and the ongoing impact of global economic conditions on customer spending, particularly in the Analytical Instruments segment.

Aug 1, 2025 8-K

Thermo Fisher Scientific 8-K Report, Financial Results (Jul 23, 2025)

Thermo Fisher reported Q2 2025 revenue of $10.85 billion, up 3% year over year, with organic growth of 2%. GAAP diluted EPS rose 6% to $4.28, helped by lower amortization of acquisition intangibles, while adjusted EPS was roughly flat at $5.36 versus $5.37. GAAP operating margin fell to 16.9% from 17.3%, and adjusted operating margin fell to 21.9% from 22.3%, so profitability slipped even as headline growth held up. Management pointed to PPI Business System cost actions and tariff-related supply chain adjustments. The quarter's weak spot was cash generation and the Analytical Instruments segment. Free cash flow fell about 34% to $1.11 billion from $1.67 billion, as operating cash flow dropped to $1.40 billion. Analytical Instruments revenue declined 3% to $1.73 billion, and its segment margin compressed sharply to 18.8% from 24.6%. Life Sciences Solutions (up 6%) and Laboratory Products and Biopharma Services (up 4%) carried growth. The filing itself contains no updated 2025 guidance. The company said it would provide revised guidance on its July 23 earnings call, so investors should weigh the filing's results against that outlook. On the balance sheet, long-term obligations rose to $33.0 billion from $29.1 billion, and the company repurchased $2.0 billion of stock in the first half. The filing also notes a post-quarter agreement to acquire Sanofi's Ridgefield, New Jersey sterile fill-finish site.

Jul 23, 2025 8-K

Thermo Fisher Scientific 8-K Report, Executive Changes (Jul 23, 2025)

Thermo Fisher Scientific Inc. (TMO) has announced a significant leadership transition within its finance department. Senior Vice President and Chief Financial Officer, Stephen Williamson, will retire effective March 31, 2026. This planned retirement marks the end of an era for the company's financial leadership, providing ample time for a smooth handover. Investors should note the timing of this transition, allowing for continuity in financial strategy and operations.

Jul 23, 2025 8-K

Thermo Fisher Scientific 8-K Report, Shareholder Vote Results (May 28, 2025)

Thermo Fisher Scientific Inc. (TMO) filed an 8-K on May 27, 2025, detailing the outcomes of its Annual Meeting of Shareholders held on May 21, 2025. The primary focus of the filing is the voting results on several key proposals. Notably, all nominated directors were overwhelmingly elected to the Board of Directors, indicating strong shareholder confidence in the current leadership and governance structure. However, a significant point for investors is the non-binding advisory vote on executive compensation, which was not approved by shareholders. This suggests a potential disconnect between shareholder expectations and the company's executive pay practices. Additionally, a shareholder proposal to remove the one-year holding period for calling a special meeting also failed to gain approval, maintaining the status quo on shareholder-initiated extraordinary actions. The ratification of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2025 received strong shareholder support.

May 28, 2025 8-K

Thermo Fisher Scientific 8-K Report, Executive Changes (May 22, 2025)

Thermo Fisher Scientific Inc. announced a significant long-term incentive award to its Chairman, President, and CEO, Marc N. Casper. The company's Board of Directors approved a 5-year performance-based restricted stock unit (RSU) award with a target grant date fair value of approximately $60 million. This award is designed to incentivize continued leadership through at least May 2030 and to drive substantial shareholder returns, specifically through outperformance in Total Shareholder Return (TSR) relative to the S&P 500. The Board's decision was based on a thorough review, highlighting Mr. Casper's extensive track record of value creation, including quadrupling annual revenue to $43 billion and achieving over 800% TSR during his tenure, significantly outperforming the S&P 500 Equal Weight Index. Investor feedback also underscored the importance of his continued leadership for long-term value creation. The award structure, with a 5-year cliff vesting and an additional deferred share delivery for up to 10 years post-grant, aims to ensure sustained alignment with shareholder interests.

May 22, 2025 10-Q

Thermo Fisher Scientific Quarterly Report for Q1 Ended Mar 29, 2025

Thermo Fisher Scientific Inc. reported a modest increase in total revenues for the first quarter of 2025, reaching $10.36 billion, up slightly from $10.34 billion in the prior year period. This growth was driven by positive contributions from the Analytical Instruments, Specialty Diagnostics, and Life Sciences Solutions segments, partially offset by a decline in the Laboratory Products and Biopharma Services segment, influenced by the moderation of COVID-19 related revenues. The company demonstrated resilience with a 15% increase in GAAP diluted earnings per share to $3.98, while adjusted diluted EPS saw a 1% rise to $5.15. Key drivers for earnings improvement included strong productivity gains and a favorable tax benefit from a domestication transaction, which helped to offset unfavorable business mix and strategic investments. From a balance sheet perspective, total assets grew to $99.04 billion, supported by robust cash and cash equivalents of $4.13 billion. The company maintained a strong liquidity position, with no outstanding borrowings under its $5 billion revolving credit facility as of quarter-end. Thermo Fisher continued its capital deployment strategy, repurchasing $2.00 billion of its common stock and paying $0.15 billion in dividends during the quarter. The company also announced a significant pending acquisition of Solventum Corporation’s Purification & Filtration business for approximately $4.1 billion, expected to close by year-end 2025, which is poised to strengthen its Life Sciences Solutions segment.

May 2, 2025 8-K

Thermo Fisher Scientific 8-K Report, Financial Results (Apr 23, 2025)

Thermo Fisher Scientific (TMO) reported first quarter 2025 results for the period ended March 29, 2025, with revenue of $10.36 billion, essentially flat versus $10.34 billion a year earlier. Organic revenue growth was just 1%, with currency translation a 1-point headwind and no contribution from acquisitions or divestitures. Profitability was mixed: GAAP diluted EPS rose 15% to $3.98, helped by lower amortization of acquisition intangibles and a lower tax provision, while adjusted EPS grew only 1% to $5.15. Adjusted operating margin contracted slightly to 21.9% from 22.0%, and GAAP operating margin improved to 16.6% from 16.1%. Restructuring costs rose to $98 million from $29 million. Cash generation weakened meaningfully. Operating cash flow fell to $723 million from $1.25 billion, and free cash flow dropped to $373 million from $908 million, driven by a $1.4 billion outflow from changes in working capital. Management nonetheless continued capital deployment: it repurchased $2.0 billion of stock, raised the dividend 10%, and agreed to acquire Solventum's Purification & Filtration business for $4.1 billion in cash. Total debt rose, with long-term obligations increasing to $31.4 billion from $29.1 billion, though cash and short-term investments also increased. The company did not provide updated 2025 guidance in this filing; it was deferred to the earnings call. For investors, the quarter shows steady but low-growth top-line performance in a more uncertain macroeconomic environment, with earnings growth driven more by share count reduction and tax and amortization effects than by operations. The key items to monitor are the revised 2025 guidance, the working capital reversal that depressed free cash flow, and the integration and leverage implications of the Solventum acquisition.

Apr 23, 2025 8-K

Thermo Fisher Scientific 8-K Report, Corporate Update (Feb 25, 2025)

Thermo Fisher Scientific Inc. (TMO) announced a significant strategic acquisition on February 25, 2025, agreeing to purchase Solventum Corporation's purification and filtration business for approximately $4.1 billion in cash. This move is expected to bolster TMO's existing portfolio within its life sciences solutions segment. The transaction is anticipated to close by the end of 2025, subject to standard closing conditions and necessary regulatory approvals. Investors should monitor the progress of these approvals and the integration process, as the company has outlined potential risks and uncertainties, including the possibility that expected benefits and synergies may not materialize as anticipated or that the transaction may not be completed within the expected timeframe.

Feb 25, 2025 10-K

Thermo Fisher Scientific Annual Report, Year Ended Dec 31, 2024

Thermo Fisher Scientific Inc. reported relatively flat revenue for the year ended December 31, 2024, compared to the previous year, with consolidated revenues of $42.88 billion. While GAAP operating income saw a 7% increase to $7.34 billion, adjusted operating income slightly decreased by 1% to $9.71 billion. Diluted earnings per share (EPS) on a GAAP basis increased by 7% to $16.53, while adjusted EPS grew by 1% to $21.86. The company experienced a significant decline in COVID-19 related sales, which impacted the Life Sciences Solutions segment with a 3% revenue decrease. However, growth in Analytical Instruments and Specialty Diagnostics, alongside a slight increase in Laboratory Products and Biopharma Services, helped offset these declines. Strategic investments in innovation and commercial capabilities were noted as drivers for growth in academic, government, industrial, and applied markets, despite a muted macroeconomic environment impacting most end markets and geographies.

Feb 20, 2025 8-K

Thermo Fisher Scientific 8-K Report, Executive Changes (Feb 19, 2025)

Thermo Fisher Scientific Inc. (TMO) announced a strategic addition to its Board of Directors with the election of Karen S. Lynch, effective February 19, 2025. Ms. Lynch brings extensive experience in the healthcare sector, notably her tenure as former president and CEO of CVS Health, where she oversaw a vast employee base and significant consumer reach. Her appointment is expected to strengthen the Board's expertise, particularly as she is anticipated to serve on the Audit Committee.

Feb 19, 2025 8-K

Thermo Fisher Scientific 8-K Report, Financial Results (Jan 30, 2025)

Thermo Fisher Scientific (TMO) reported fourth quarter and full year 2024 results on January 30, 2025, showing a strong close to the year but flat annual performance. Q4 revenue grew 5% to $11.40 billion, with organic revenue growth of 4% and Core organic growth of 5%. GAAP diluted EPS rose 14% to $4.78, and adjusted EPS grew 8% to $6.10, with adjusted operating margin expanding to 23.9% from 23.4%. For the full year, revenue was essentially flat at $42.88 billion, with organic and Core organic growth both at 0%. Adjusted EPS rose 1% to $21.86, while adjusted operating income declined to $9.71 billion from $9.81 billion and adjusted operating margin slipped to 22.6% from 22.9%. The balance sheet and capital allocation were central to the year. Thermo Fisher completed the Olink acquisition, spent $3.1 billion on acquisitions net of cash acquired, and returned $4.6 billion to shareholders through buybacks ($4.0 billion) and dividends ($583 million). Free cash flow rose 4% to $7.32 billion. Cash and cash equivalents fell to $4.0 billion from $8.1 billion, partly offset by $1.56 billion in short-term investments, and total debt-related obligations declined, with long-term obligations down to $29.1 billion from $31.3 billion. Management emphasized that the company exited 2024 with momentum and said it is well positioned for 2025. Full-year 2025 guidance was not included in the release and was to be provided on the earnings call the same morning. Investors should note that the Q4 improvement reflects a sharp turn from the flat full-year trend, and that GAAP results benefited from lower amortization and restructuring-related charges that are excluded from adjusted metrics.

Jan 30, 2025 10-Q

Thermo Fisher Scientific Quarterly Report for Q3 Ended Sep 28, 2024

Thermo Fisher Scientific Inc. reported steady revenue performance for the third quarter of fiscal year 2024, with total revenues reaching $10.598 billion, largely in line with the prior year's $10.574 billion. For the nine-month period, revenues saw a slight decrease of 2% to $31.484 billion from $31.971 billion in the prior year. The company experienced a year-over-year decrease in diluted EPS for the quarter to $4.25 from $4.42, but a growth in diluted EPS for the nine-month period to $11.75 from $11.25. This performance reflects a normalization of COVID-19 related demand and a challenging macroeconomic environment impacting revenue growth across several segments, particularly Life Sciences Solutions and Laboratory Products and Biopharma Services. The company continues to strategically invest in innovation and commercial capabilities. The acquisition of Olink Holding AB in July 2024 for $3.146 billion, focused on enhancing its proteomics capabilities within the Life Sciences Solutions segment, is a key strategic move. Despite revenue headwinds from declining COVID-19 related demand, the company is demonstrating operational resilience with strong productivity improvements and cost management, as evidenced by the growth in GAAP operating income for the nine-month period and a solid operating margin. Management remains confident in its ability to meet future cash requirements through existing cash, operating cash flow, and available credit, while continuing to return capital to shareholders through share repurchases and dividends.

Nov 1, 2024 8-K

Thermo Fisher Scientific 8-K Report, Financial Results (Oct 23, 2024)

Thermo Fisher Scientific (TMO) reported third quarter 2024 results for the fiscal quarter ended September 28, 2024. Revenue was $10.60 billion, essentially flat versus $10.57 billion in the prior-year quarter, though management said revenue growth, organic revenue growth and Core organic revenue growth all improved sequentially from Q2. GAAP diluted EPS was $4.25, down from $4.42, and GAAP operating margin slipped to 17.3% from 17.6%. Adjusted EPS was $5.28, down from $5.69 a year earlier, and adjusted operating margin contracted to 22.3% from 24.2%, driven largely by lower profitability in Laboratory Products and Biopharma Services (segment margin 13.5% vs. 16.4%). On the balance sheet and cash flow side, nine-month operating cash flow rose to $5.38 billion from $4.68 billion and free cash flow increased to $4.50 billion from $3.69 billion. The company spent $3.0 billion on share repurchases and $3.1 billion on acquisitions over the nine months, while cash and equivalents fell to $4.6 billion from $8.1 billion at year-end 2023, partly because of $2.0 billion placed into short-term investments. Goodwill rose to $46.7 billion, reflecting recent acquisitions. Total debt (short-term plus long-term obligations) was roughly $35.3 billion at quarter end. Management raised the low end of full-year 2024 adjusted EPS guidance to $21.35–$22.07 from $21.29–$22.07, and reaffirmed revenue guidance of $42.4–$43.3 billion. The narrow guidance raise means the midpoint of adjusted EPS guidance moves only marginally, and the outlook implies a stronger fourth quarter than the year-to-date results alone would suggest. Investors should weigh the sequential improvement and cash generation against continued margin pressure and flat top-line growth.

Oct 23, 2024 10-Q

Thermo Fisher Scientific Quarterly Report for Q2 Ended Jun 29, 2024

Thermo Fisher Scientific Inc. (TMO) reported its second-quarter and first-half 2024 results, demonstrating resilience amidst a moderating macroeconomic environment. Total revenues saw a slight decline year-over-year for both periods, primarily due to a decrease in COVID-19 related product demand. However, the company continues to show strong operational execution with an increase in GAAP operating income and margin, driven by productivity improvements and a favorable business mix, partially offset by lower restructuring charges compared to the prior year. Adjusted operating income and margin remained stable, highlighting the company's consistent performance. The company also announced the significant acquisition of Olink Holding AB, a move aimed at bolstering its Life Sciences Solutions segment in the high-growth proteomics market. This strategic acquisition, along with ongoing focus on innovation and customer partnerships, positions Thermo Fisher for future growth. Despite the revenue headwinds from declining COVID-19 related sales, the company's strong cash flow generation and robust balance sheet provide confidence in its ability to navigate current market conditions and pursue strategic growth initiatives.

Aug 2, 2024 8-K

Thermo Fisher Scientific 8-K Report, Financial Results (Jul 24, 2024)

Thermo Fisher Scientific reported second quarter 2024 results for the quarter ended June 29, 2024. Revenue was $10.54 billion, down 1% from $10.69 billion a year earlier, with organic revenue down 1% and Core organic revenue growth flat. Profitability was the bright spot on a GAAP basis: diluted EPS rose 15% to $4.04, and GAAP operating margin expanded to 17.3% from 14.8%, helped by lower restructuring charges and lower amortization of acquisition intangibles. Adjusted EPS rose 4% to $5.37, while adjusted operating income slipped to $2.35 billion from $2.37 billion, with adjusted operating margin edging up to 22.3% from 22.2%. Cash generation was strong. Free cash flow for the quarter was $1.67 billion, up from $1.26 billion, and year-to-date free cash flow reached $2.58 billion versus $1.54 billion. Management raised full-year 2024 guidance modestly: revenue to $42.4–43.3 billion (low end raised from $42.3 billion) and adjusted EPS to $21.29–22.07 (from $21.14–22.02). Management also noted the completed acquisition of Olink shortly after quarter end. The results point to flat underlying demand offset by margin discipline and cost control, with the guidance change being incremental rather than a meaningful shift in outlook. Investors should note that the Life Sciences Solutions segment was the main driver of margin improvement, with segment margin rising to 36.7%, while Laboratory Products and Biopharma Services margin fell to 12.9% from 14.1%. Balance sheet activity included $3.0 billion of share repurchases in the first half and $1.2 billion of new debt issuance, while cash declined and short-term investments rose. Because the filing is a Form 8-K furnishing the earnings release, the information is not deemed filed under Section 18 of the Exchange Act.

Jul 24, 2024 8-K

Thermo Fisher Scientific 8-K Report, Corporate Update (Jul 10, 2024)

Thermo Fisher Scientific Inc. (TMO) has filed an 8-K report on July 10, 2024, detailing the expiration and results of a tender offer conducted by its wholly owned subsidiary, Orion Acquisition AB. The tender offer aimed to acquire all outstanding common shares and American Depositary Receipts (ADRs) of Olink Holding AB (publ). This event signifies a major step towards Thermo Fisher's potential acquisition of Olink, a development that could have significant strategic and financial implications for the company and its shareholders.

Jul 10, 2024 8-K

Thermo Fisher Scientific 8-K Report, Shareholder Vote Results (May 24, 2024)

This 8-K filing from Thermo Fisher Scientific Inc. reports the outcomes of their Annual Meeting of Shareholders held on May 22, 2024. The primary focus is on the voting results for several key proposals. All incumbent directors were overwhelmingly re-elected to the Board, indicating strong shareholder confidence in the current leadership and governance. Additionally, shareholders approved the executive compensation plan on a non-binding advisory basis, and ratified the appointment of PricewaterhouseCoopers LLP as the independent auditor for the upcoming fiscal year.

May 24, 2024 10-Q

Thermo Fisher Scientific Quarterly Report for Q1 Ended Mar 30, 2024

Thermo Fisher Scientific Inc. (TMO) reported its first-quarter 2024 financial results, showing total revenues of $10.35 billion, a decrease of 3% compared to the prior year's $10.71 billion. This decline was primarily driven by a decrease in Life Sciences Solutions and Analytical Instruments segments, partly offset by stable performance in Specialty Diagnostics and Laboratory Products and Biopharma Services. Despite the revenue dip, operating income saw a modest 6% increase to $1.66 billion, leading to diluted earnings per share (EPS) of $3.46, up from $3.32 in the first quarter of 2023. The company continues to navigate a complex market, with a decrease in COVID-19 related revenue impacting performance. However, management highlights strong productivity improvements and strategic investments as key drivers for future growth. The company also announced its intent to acquire Olink Holding AB for approximately $3.1 billion, expected to close mid-year 2024, which is anticipated to enhance its proteomics capabilities.

May 3, 2024 8-K

Thermo Fisher Scientific 8-K Report, Financial Results (Apr 24, 2024)

Thermo Fisher Scientific reported first-quarter 2024 results that were mixed: revenue declined 3% year over year to $10.34 billion, with organic revenue down 4% and Core organic revenue down 3%. Profitability held up better than the top line. GAAP diluted EPS rose 4% to $3.46, GAAP operating margin expanded to 16.1% from 14.6%, and adjusted EPS increased 2% to $5.11 with adjusted operating margin at 22.0%. Free cash flow more than tripled to $908 million from $277 million, driven by higher operating cash flow of $1.25 billion. The company raised its low end of full-year 2024 revenue guidance to $42.3 to $43.3 billion (previously $42.1 to $43.3 billion) and raised its adjusted EPS guidance to $21.14 to $22.02 (previously $20.95 to $22.00). The raise is modest, and management attributed it to stronger operational performance. Capital deployment was active: the company repurchased $3.0 billion of stock and increased its dividend by 11%. Cash and cash equivalents fell to $5.5 billion from $8.1 billion, partly because of $1.76 billion in investment purchases and the buybacks, while total debt rose to roughly $35.6 billion from $34.9 billion after a $1.2 billion debt issuance. The weakest area was Life Sciences Solutions, where revenue fell about 12.5% to $2.29 billion, although segment margin expanded to 36.8% from 32.0%. Analytical Instruments declined about 2%, Specialty Diagnostics was flat, and Laboratory Products and Biopharma Services was roughly flat to slightly down. The filing also references the pending acquisition of Olink, and investors will likely focus on how that deal affects leverage and growth in future periods.

Apr 24, 2024 10-K

Thermo Fisher Scientific Annual Report, Year Ended Dec 31, 2023

Thermo Fisher Scientific Inc. reported a 5% decrease in revenue for the fiscal year ended December 30, 2023, primarily driven by a significant decline in COVID-19 related sales, which fell from $3.11 billion in 2022 to $0.33 billion in 2023. This reduction was partially offset by strong performance in the Analytical Instruments segment and the Laboratory Products and Biopharma Services segment, which saw revenue increases of 10% and 2% respectively on an organic basis. The company also executed significant restructuring actions, incurring $0.2 billion in charges to streamline operations, which are expected to yield $0.5 billion in annual cost savings. The company continues to focus on its three-pillar growth strategy: high-impact innovation, trusted partner status with customers, and an unparalleled commercial engine. Strategic acquisitions in 2023 included The Binding Site Group for specialty diagnostics and CorEvitas, LLC for real-world evidence solutions. Thermo Fisher also announced a proposed acquisition of Olink Holding AB for approximately $3.1 billion to expand its proteomics capabilities, subject to regulatory approvals and tender offer completion. Despite the revenue decline, the company maintained a strong free cash flow of $7.014 billion and returned capital to shareholders through share repurchases totaling $3.00 billion and dividend payments. The company ended the year with a robust cash position of $8.077 billion.

Feb 22, 2024 8-K

Thermo Fisher Scientific 8-K Report, Financial Results (Jan 31, 2024)

Thermo Fisher Scientific (TMO) reported fourth-quarter and full-year 2023 results on January 31, 2024, showing a clear year-over-year revenue decline driven by the post-pandemic normalization in COVID-19 testing and weaker demand in its Life Sciences Solutions segment. Q4 revenue fell 5% to $10.89 billion (Core organic growth -4%), while full-year revenue declined 5% to $42.86 billion (Core organic growth +1%). GAAP diluted EPS rose 5% in Q4 to $4.20, but full-year GAAP EPS fell to $15.45 from $17.63 and adjusted EPS fell to $21.55 from $23.24, reflecting lower volumes, higher restructuring charges ($459 million vs. $114 million) and higher interest expense ($1.375 billion vs. $726 million) tied to acquisition financing. Cash generation remained strong, with full-year operating cash flow of $8.41 billion and free cash flow of $7.01 billion, up about 1% from 2022. Management returned $3.5 billion to shareholders through buybacks ($3.0 billion) and dividends ($523 million) and completed the acquisitions of The Binding Site and CorEvitas, while announcing the pending acquisition of Olink Holding AB. Full-year 2024 guidance calls for revenue of $42.1 to $43.3 billion and adjusted EPS of $20.95 to $22.00, implying roughly flat to modestly lower results versus 2023 and signaling that management expects only a gradual recovery. For investors, the key takeaways are the continued softness in Life Sciences Solutions and the step-down in profitability, offset by resilient Analytical Instruments growth (up 10% for the year), Specialty Diagnostics margin expansion, and the company's strong cash flow and capital return capacity. Net debt has increased with the acquisition activity, so the pace of the Olink integration and the timing of demand recovery in bioprocessing and academic markets will be the main variables to monitor.

Jan 31, 2024 8-K

Thermo Fisher Scientific 8-K Report, Material Agreement (Dec 5, 2023)

Thermo Fisher Scientific Inc. (TMO) has filed an 8-K report detailing a significant debt issuance. On December 5, 2023, the company successfully raised approximately $2.5 billion in aggregate principal amount through the public offering of senior notes across three tranches: $1 billion of 5.000% Senior Notes due 2026, $1 billion of 5.000% Senior Notes due 2029, and $500 million of 5.200% Senior Notes due 2034. These notes are general unsecured obligations, ranking equally with existing unsecured debt and senior to subordinated debt, but are effectively subordinated to secured debt and structurally subordinated to subsidiary debt. The net proceeds from this offering are earmarked for general corporate purposes. This can include strategic initiatives such as acquisitions, debt repayment or refinancing, working capital needs, capital expenditures, or equity repurchases. The company may also temporarily invest the proceeds in liquid investments until their intended use. The issuance, governed by a base indenture and a supplemental indenture, includes standard provisions for redemption, a change of control offer to purchase, and limited negative covenants that restrict the incurrence of secured debt and sale-leaseback transactions involving principal properties, as well as limits on mergers and asset sales.

Dec 5, 2023 8-K

Thermo Fisher Scientific 8-K Report, Temporary Suspension of Trading Under Employee Benefit Plans (Nov 7, 2023)

Thermo Fisher Scientific (TMO) filed this Form 8-K on November 7, 2023 to disclose a temporary blackout period for its Thermo Fisher Scientific Inc. 401(k) Plan, which is transitioning to a new plan administrator. The blackout is expected to begin at 4:00 pm Eastern Time on Thursday, December 21, 2023, and end during the week of January 14, 2024. During this window, participants cannot change contribution rates or investment allocations, make loan repayments or new loans, or take withdrawals or distributions, including transactions involving TMO common stock held in the plan. Because the blackout affects 50% or more of plan participants for more than three consecutive business days, Regulation BTR and Section 306 of the Sarbanes-Oxley Act require the company to notify its directors and executive officers. Those insiders are barred from buying, selling, acquiring, or transferring TMO stock (including derivatives) acquired through their board or executive service during the blackout, even if they are not plan participants. Exemptions exist, such as qualified Rule 10b5-1 plan transactions, but insiders must confirm with the legal department before trading. Violations can lead to disgorgement of profits and civil or criminal penalties. For investors, this is an administrative filing rather than a financial-performance disclosure. It contains no earnings, guidance, or material operational news. The main takeaways are the timing of the blackout, which overlaps the year-end period when insider trading is already restricted under the company's policy, and the limited practical effect on public shareholders, whose trading is unaffected. Any delay in the transition schedule would be communicated by the company.

Nov 7, 2023 10-Q

Thermo Fisher Scientific Quarterly Report for Q3 Ended Sep 30, 2023

Thermo Fisher Scientific Inc. reported total revenues of $10.57 billion for the third quarter of 2023, a slight decrease of 1% year-over-year, and $31.97 billion for the first nine months, down 4%. This decline is largely attributable to the significant reduction in COVID-19 related product demand, which impacted the Life Sciences Solutions and Specialty Diagnostics segments most notably. Despite the revenue headwinds, the company demonstrated strong operational execution, with adjusted operating income increasing by 8% year-over-year for the quarter, driven by robust productivity improvements and effective price realization. This points to the resilience of its core business and its ability to manage costs effectively amidst a challenging macroeconomic environment. The company continues to focus on strategic growth through innovation, its partner status with customers, and its commercial engine. A significant development during the quarter was the proposed acquisition of Olink Holding AB for approximately $3.1 billion, which is expected to close by mid-year 2024 and will enhance its capabilities in next-generation proteomics. This strategic acquisition, alongside ongoing investments in R&D and operational efficiencies, underscores Thermo Fisher's commitment to long-term growth and market leadership in the life sciences and diagnostics sectors.

Nov 3, 2023 8-K

Thermo Fisher Scientific 8-K Report, Financial Results (Oct 25, 2023)

Thermo Fisher Scientific (TMO) reported third quarter 2023 results on October 25, 2023. Revenue was $10.57 billion, down 1% year over year, with Core organic revenue growth of 1%. Profitability was the bright spot: GAAP diluted EPS rose 17% to $4.42, and adjusted EPS rose 12% to $5.69. GAAP operating margin expanded 160 basis points to 17.6%, and adjusted operating margin expanded 200 basis points to 24.2%. Management attributed the margin gains to its PPI Business System and cost discipline, while acknowledging that macroeconomic conditions weakened further during the quarter. Management lowered full-year 2023 guidance, now expecting revenue of $42.7 billion, 1% Core organic growth, and adjusted EPS of $21.50. Nine-month results show the pressure more clearly: revenue fell 4.4% to $31.97 billion, and Life Sciences Solutions segment income dropped sharply as COVID-related demand normalized. Free cash flow for the nine months was $3.69 billion, down from $3.99 billion, while the company returned $3.0 billion through share repurchases. Net debt rose as long-term obligations increased to $30.5 billion, reflecting debt raised to fund acquisitions. The most significant strategic item is the pending acquisition of Olink Holding AB for a net purchase price of about $3.1 billion, which adds next-generation proteomics capabilities. The filing is a earnings disclosure furnished under Item 2.02, so it is not deemed filed under Section 18 of the Exchange Act. Investors should weigh the resilient margin and EPS performance against weakening top-line demand, the lowered guidance, and the integration and financing considerations associated with Olink.

Oct 25, 2023 8-K

Thermo Fisher Scientific 8-K Report, Corporate Update (Oct 17, 2023)

On October 17, 2023, Thermo Fisher Scientific (NYSE: TMO) and Olink Holding AB (Nasdaq: OLK) announced that Olink's board approved a proposal for Thermo Fisher to acquire Olink for $26.00 per common share or ADS in cash, via a tender offer. The price represents a premium of approximately 74% to Olink's closing price on October 16, 2023, and values Olink at roughly $3.1 billion including about $143 million of net cash. Olink, a provider of next-generation proteomics solutions using its Proximity Extension Assay technology, will become part of Thermo Fisher's Life Sciences Solutions segment. The filing itself is a brief Item 8.01 (Other Events) report that attaches the joint press release as Exhibit 99.1; the tender offer has not yet commenced. Deal support is strong: Summa Equity AB, Olink's largest shareholder, together with other shareholders and management, holding more than 63% of Olink's common shares, have signed support agreements to tender into the offer. Closing is expected by mid-2024 and remains subject to customary conditions, including regulatory approvals and completion of the tender offer. Thermo Fisher plans to fund the purchase with cash on hand and debt financing. Financially, management expects Olink to exceed $200 million of revenue in 2024 and to grow mid-teens organically under Thermo Fisher. The deal is expected to be dilutive to adjusted EPS by $0.17 in the first full year of ownership, or accretive by $0.10 excluding financing costs and non-cash deal-related equity compensation. Thermo Fisher targets approximately $125 million of adjusted operating income from revenue and cost synergies by year five after close. These figures are management projections and non-GAAP measures.

Oct 17, 2023 8-K

Thermo Fisher Scientific 8-K/A Report, Executive Changes (Sep 21, 2023)

Thermo Fisher Scientific Inc. (TMO) has filed an amendment to its previously submitted Current Report on Form 8-K, clarifying the committee assignments for a newly elected director. The amendment, filed on September 21, 2023, confirms that Jennifer "Jenny" Johnson, who was elected to the Board of Directors on July 13, 2023, has now been appointed to the Audit Committee. This appointment is effective as of September 21, 2023. While this filing primarily addresses a procedural update regarding committee appointments, it is important for investors to note that Ms. Johnson's role on the Audit Committee provides oversight of the company's financial reporting and internal controls. Investors often view committee assignments, particularly to the Audit Committee, as a key indicator of a director's responsibilities and the company's commitment to robust financial governance.

Sep 21, 2023 8-K

Thermo Fisher Scientific 8-K Report, Material Agreement (Aug 10, 2023)

Thermo Fisher Scientific Inc. (TMO) has announced a significant debt offering, issuing a total of $2.95 billion in aggregate principal amount of Senior Notes across four tranches with varying maturity dates and interest rates. These notes include $600 million of 4.953% Senior Notes due 2026, $750 million of 4.977% Senior Notes due 2030, $1 billion of 5.086% Senior Notes due 2033, and $600 million of 5.404% Senior Notes due 2043. The company has also entered into cross-currency swaps totaling $2.95 billion. The primary stated use of the net proceeds, estimated at approximately $2.92 billion after expenses, is to redeem outstanding Floating Rate Senior Notes maturing in October 2023 and October 2024, totaling $1 billion. The remaining proceeds are earmarked for general corporate purposes, which may include acquisitions, debt repayment, working capital, capital expenditures, equity repurchases, or temporary investments. The issuance of these new notes adds to the company's long-term debt structure and is governed by an indenture with standard covenants related to liens, sale and lease-back transactions, and mergers or consolidations.

Aug 10, 2023 8-K

Thermo Fisher Scientific 8-K Report, Regulation FD Disclosure (Aug 8, 2023)

Thermo Fisher Scientific Inc. (TMO) has announced significant debt management activities through an 8-K filing dated August 8, 2023. The company is initiating the redemption of its $1.0 billion aggregate principal amount of Floating Rate Senior Notes due 2023 and 2024. This redemption is scheduled to occur on August 18, 2023, with the notes being repurchased at par value plus accrued interest. To finance this debt retirement, Thermo Fisher successfully priced a substantial new debt offering totaling $2.75 billion across multiple tranches with varying maturity dates and fixed interest rates. The company intends to utilize the proceeds from this new offering to fund the upcoming redemption. This strategic move suggests a proactive approach to optimizing the company's capital structure by replacing floating-rate debt with fixed-rate obligations, potentially locking in lower interest costs and enhancing financial predictability.

Aug 8, 2023 10-Q

Thermo Fisher Scientific Quarterly Report for Q3 Ended Jul 1, 2023

Thermo Fisher Scientific Inc. (TMO) reported revenues of $10.7 billion for the third quarter of 2023, a slight decrease of 3% year-over-year, impacted by the ongoing decline in COVID-19 related sales and a challenging macroeconomic environment. Despite the revenue dip, the company demonstrated resilience through strong execution of its growth strategy and productivity improvements. For the six-month period, revenues were $21.4 billion, down 6% year-over-year, also heavily influenced by the normalization of COVID-19 demand. The company's operational performance was marked by a 21% decrease in GAAP operating income to $1.6 billion for the quarter, and a 35% decrease to $3.1 billion for the six-month period, largely due to lower COVID-19 related revenues and increased strategic growth investments. However, adjusted operating income, which excludes certain items, showed a more moderate decline, reflecting the underlying operational strength. The balance sheet remains robust, although cash and cash equivalents decreased significantly to $3.1 billion from $8.5 billion, primarily due to significant capital deployment activities including acquisitions and share repurchases.

Aug 4, 2023 8-K

Thermo Fisher Scientific 8-K Report, Financial Results (Jul 26, 2023)

Thermo Fisher Scientific (TMO) reported second quarter 2023 results for the fiscal quarter ended July 1, 2023. Revenue declined 3% year over year to $10.69 billion (from $10.97 billion), with Core organic revenue growth of 2% and COVID-19 testing revenue of $0.08 billion. GAAP diluted EPS fell to $3.51 from $4.22, and GAAP operating margin compressed to 14.8% from 18.2%, largely reflecting $183 million of restructuring costs. Adjusted EPS was $5.15 versus $5.51 a year earlier, and adjusted operating margin declined to 22.2% from 23.7%. Management attributed the weakness to a more challenging macroeconomic environment, including slower economic activity in China and more cautious customer spending. The company cut its full-year 2023 guidance, now expecting revenue of $43.4 to $44.0 billion, Core organic growth of 2% to 4%, and adjusted EPS of $22.28 to $22.72. Cash flow remained solid, with six-month free cash flow of $1.54 billion, though that was down from $2.60 billion a year earlier. Cash fell sharply to $3.13 billion as the company funded $3.0 billion of share repurchases and $2.75 billion of acquisitions, including the pending CorEvitas deal for roughly $0.9 billion announced after quarter end. Investors should weigh the guidance reduction and margin pressure against the company's capital return activity, pipeline of new product launches, and its stated ability to navigate the cycle. This 8-K is a Form 8-K Item 2.02 disclosure furnishing the earnings press release as Exhibit 99.1. Per the filing, the information is furnished rather than filed, so it is not subject to Section 18 liability unless specifically incorporated elsewhere.

Jul 26, 2023